In fact, the dismal outcomes observed in GATA-3 PTCL, as defined by immunohistochemical staining for GATA-3 alone, following multiagent, anthracycline-based chemotherapy may suggest that this approach is futile in these patients (37, 39, 48, 49). The gene discussed is GATA3; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.